Lisa Johnson-Pratt - 14 Jun 2022 Form 4 Insider Report for Tracon Pharmaceuticals, Inc.

Role: Director
Signature: /s/ Scott B. Brown, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 14 Jun 2022
Net transactions value: $0
Form type: 4
Filing time: 16 Jun 2022, 21:11:34 UTC
Previous filing: 27 May 2022
Next filing: 21 Apr 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TCON	Director Stock Option (Right to Buy)	Award	$0	+15,750		$0.000000	15,750	14 Jun 2022	Common Stock	15,750	$1.30	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares subject to the option shall vest and become exercisable on the earlier of the first anniversary of the grant date set forth in column 3 above or the date of the next annual meeting of the Company's stockholders, subject to the optionee's Continuous Service (as defined in the Company's 2015 Equity Incentive Plan (the "Plan")) and accelerated on the closing of a Change of Control (as defined in the Plan).

Content

The shares subject to the option shall vest and become exercisable on the earlier of the first anniversary of the grant date set forth in column 3 above or the date of the next annual meeting of the Company's stockholders, subject to the optionee's Continuous Service (as defined in the Company's 2015 Equity Incentive Plan (the "Plan")) and accelerated on the closing of a Change of Control (as defined in the Plan).